"First treatment for macular degeneration now available in UK"
The Daily Telegraph on Friday 8th of March ran this article about Valeda Photobiomodulation treatment
Macular degeneration sufferers could keep sight with light therapy (telegraph.co.uk)
This article proudly marks the first UK press release about an innovative treatment that has garnered positive attention.
The Macular Disease Society has expressed encouraging sentiments regarding this advancement, highlighting its potential impact on those affected by macular diseases.
For the past six months, I have been actively participating in this treatment and am optimistic about the initial outcomes I've observed. The regimen, followed by the trial participants, involved nine sessions of light therapy, conducted three times annually over a span of two years. This methodical approach is reflective of the nature of dry macular degeneration—a condition that progresses slowly, necessitating a treatment that mirrors its gradual pace.
The treatment in question, Photobiomodulation, targets the mitochondria, the 'powerhouses' of cells, enhancing their efficiency. This boost enables the retinal cells to more effectively carry out their functions, particularly the reabsorption of drusen—waste products that accumulate in dry macular degeneration and impair vision.
We are committed to closely observing and documenting the experiences of our patients undergoing this treatment through an ongoing observational study. The anticipation is building for the forthcoming publication of the 2-year LightSite 3 randomized trial data, which promises to provide further insight into the efficacy and benefits of this promising treatment.
Mr Lee has a dedicate website for this treatment